Looming Velcade freefall shows why Takeda paid big for Shire
admin 14th May 2018 Uncategorised 0The multiple myeloma blockbuster Velcade has been Takeda’s cash cow for years, but those sales are starting to dry up, with a more than 30% drop expected this year, executives said in the company’s year-end earnings release. The Shire buyout will fill that gap—and far more.
More: Looming Velcade freefall shows why Takeda paid big for Shire
Source: fierce